Tharimmune Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Bridgewater, New Jersey and currently employs 2 full-time employees. The company went IPO on 2022-01-12. Tharimmune, Inc. is a clinical-stage biotechnology company. The firm is engaged in developing a portfolio of therapeutic candidate for inflammatory and immunologic conditions. The company has a transmucosal film product, TH104 in Phase I clinical development, two bispecific candidates and a Picobody candidate in pre-clinical development. TH104 is a transmucosal buccal film embedded with the active compound nalmefene onto a thin film which adheres inside of the mouth on the cheek and biodegrades. TH104 is an ideal product candidate for multiple liver-related and other pruritogenic inflammatory conditions. The company is also developing an early-stage pipeline of novel therapeutic candidates targeting validated high value immune-oncology (IO) targets including human epidermal growth factor (EGF) receptor 2 (HER2), human EGF receptor 3 (HER3) and programmed cell death protein (PD-1). The firm is developing antibodies, including bispecific antibodies, antibody drug conjugates (ADCs) and others.

THAR Profile, Market Tickers and Other

THAR profile